Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.

Ocean Biomedical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY POISED TO ENTER BOOMING BISPECIFIC ANTIBODY MARKET AMID GROWING PHARMA INTEREST PROVIDENCE, RI, FEB. 10, 2025 (GLOBE NEWSWIRE) -- OCEAN BIOMEDICAL (NASDAQ: OCEA) TODAY ANNOUNCED NEWLY PUBLISHED RESEARCH FINDINGS DEMONSTRATING THE ABILITY OF ITS PROPRIETARY CANCER IMMUNOTHERAPY CANDIDATES TO FAVORABLY INTERACT WITH TYROSINE KINASE INHIBITORS (TKI), SUCH AS OSIMERTINIB THAT ARE USED TO TREAT NON-SMALL CELL LUNG CANCER (NSCLC). SPECIFICALLY, THEY DEMONSTRATE THAT OCEAN'S IMMUNOTHERAPY CANDIDATES PROVIDE SYNERGY WITH THE TKI THERAPIES (GEFITINIB AND OSIMERTINIB) TO SUPPRESS TUMOR GROWTH AND PROGRESSION.

OCEAN BIOMEDICAL ANNOUNCES BREAKTHROUGH FINDINGS IN EGFR-MUTANT LUNG CANCER AND PLANS FOR FDA ALIGNMENT ON NEXT-STAGE DEVELOPMENT

PROVIDENCE, RI, JAN. 29, 2025 (GLOBE NEWSWIRE) -- OCEAN BIOMEDICAL (NASDAQ: OCEA) ANNOUNCED TODAY THAT ITS SCIENTIFIC CO-FOUNDER, DR. JONATHAN KURTIS, MD, PHD, AND HIS RESEARCH TEAM HAVE RECEIVED ADDITIONAL SIGNIFICANT FUNDING FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) TO ADVANCE THEIR GROUNDBREAKING MALARIA VACCINE RESEARCH. IN PARALLEL, RECENT U.S. FOOD AND DRUG ADMINISTRATION (FDA) GUIDANCE ON LIPID-ENCAPSULATED VACCINES MAY OFFER AN EXPEDITED DEVELOPMENT PATHWAY FOR THEIR INNOVATIVE APPROACH.

OCEAN BIOMEDICAL ADVANCES MALARIA VACCINE RESEARCH WITH NEW NIH FUNDING AND EXPEDITED DEVELOPMENT PATHWAY

PROVIDENCE, RHODE ISLAND, NOV. 22, 2024 (GLOBE NEWSWIRE) -- OCEAN BIOMEDICAL, INC. (NASDAQ: OCEA), TODAY ANNOUNCED THAT ON NOVEMBER 18, 2024, IT RECEIVED A NOTICE FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) STATING THAT BECAUSE THE COMPANY HAS NOT YET FILED ITS QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2024 (THE FORM 10-Q), THE COMPANY IS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5250(C)(1), WHICH REQUIRES LISTED COMPANIES TO TIMELY FILE ALL REQUIRED PERIODIC REPORTS WITH THE SECURITIES AND EXCHANGE COMMISSION (THE SEC).

OCEAN BIOMEDICAL, INC. ANNOUNCES RECEIPT OF NOTICE FROM NASDAQ REGARDING LATE FILING OF QUARTERLY REPORT ON FORM 10-Q

PROVIDENCE, RHODE ISLAND, OCT. 22, 2024 (GLOBE NEWSWIRE) -- OCEAN BIOMEDICAL, INC. (NASDAQ: OCEA), TODAY ANNOUNCED THAT ON OCTOBER 16, 2024, IT RECEIVED A STAFF DETERMINATION LETTER FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) STATING THAT ON APRIL 18, 2024, MAY 22, 2024, AND AUGUST 19, 2024, STAFF NOTIFIED THE COMPANY THAT IT DID NOT COMPLY WITH NASDAQ'S FILING REQUIREMENTS SET FORTH IN LISTING RULE 5250(C)(1) (THE RULE) BECAUSE IT HAD NOT FILED ITS FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2024 (THE FORM 10-K), AND ITS FORMS 10-Q FOR THE PERIODS ENDED MARCH 31, 2024 AND JUNE 30, 2024 (THE FORMS 10-Q), RESPECTIVELY. BASED ON ITS REVIEW AND THE MATERIALS SUBMITTED ON JUNE 17, 2024 AND AUGUST 27, 2024, STAFF GRANTED THE COMPANY AN EXCEPTION UNTIL OCTOBER 14, 2024, TO REGAIN COMPLIANCE WITH THE RULE. UPON FURTHER REVIEW, STAFF DETERMINED THAT THE COMPANY DID NOT MEET THE TERMS OF THE EXCEPTION. SPECIFICALLY, THE COMPANY HAS NOT FILED THE EITHER ITS FORM 10-K OR FORMS 10-Q AS REQUIRED BY THE RULE. THE COMPANY WILL APPEAL STAFF'S DETERMINATION TO A HEARINGS PANEL (THE PANEL), PURSUANT TO THE PROCEDURES SET FORTH IN THE NASDAQ LISTING RULE 5800 SERIES.

OCEAN BIOMEDICAL, INC. ANNOUNCES RECEIPT OF NASDAQ STAFF DETERMINATION LETTER

THIS LICENSE COVERS FIRST-IN-CLASS SMALL MOLECULE YKL-40 INHIBITORS, INCLUDING THE LEAD MOLECULE OAT-3912, WHICH HAS SHOWN POTENTIAL THERAPEUTIC BENEFITS IN PRECLINICAL MODELS IN VARIOUS CANCERS AS WELL AS INFLAMMATORY AND FIBROTIC DISEASES, OFFERING A NOVEL APPROACH TO TREATING THESE CONDITIONS. IN ADDITION, THE LICENSE COVERS A PATENT PENDING FOR A MOLECULAR SCREENING TEST FOR FURTHER THE CONTINUATION OF THE PROGRAM AND THE DEVELOPMENT OF NEW YKL-40 INHIBITORS.

MOLECURE (WSE: MOC) AND NASDAQ-LISTED BIOTECHNOLOGY COMPANY OCEAN BIOMEDICAL (NASDAQ: OCEA) SIGN AN EXCLUSIVE LICENSING AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF SELECTIVE YKL-40 INHIBITORS.

OCEAN BIOMEDICAL'S ANTI-CHI3L1 PATENT COVERAGE INCLUDES MULTIPLE METHODS OF USE FOR TARGETING A BROAD RANGE OF CANCERS THAT INCLUDE LUNG CANCER, GLIOBLASTOMA, PROSTATE CANCER, MELANOMA, AND BREAST CANCER

OCEAN BIOMEDICAL, INC. (NASDAQ: OCEA) ANNOUNCES PUBLICATION OF NEW DATA DEEPENING UNDERSTANDING OF NOVEL CANCER IMMUNOTHERAPY TREATMENT APPROACH TARGETING CHI3L1 AND ITS ABILITY TO INHIBIT ANTI-TUMOR AND RELATED TISSUE REMODELING RESPONSES

PROVIDENCE, RI, AUG. 27, 2024 (GLOBE NEWSWIRE) -- OCEAN BIOMEDICAL (NASDAQ: OCEA ) ANNOUNCED TODAY THAT ITS SCIENTIFIC CO-FOUNDER DR. JONATHAN KURTIS, MD, PHD, HAS BEEN ISSUED A KEY U.S. PATENT FOR HIS GROUNDBREAKING MALARIA THERAPEUTIC ANTIBODY DISCOVERY THAT TARGETS PFGARP. SINCE PUBLICIZING NEWS OF HIS ORIGINAL RESEARCH ON PFGARP AND ITS CRITICAL ROLE IN THE MALARIA CYCLE IN THE JOURNAL NATURE , DR. KURTIS AND HIS TEAM HAVE BEEN WORKING TO DEEPEN THEIR UNDERSTANDING OF HOW IT NATURALLY TRIGGERS THE DEATH OF MALARIA PARASITES, AND THEIR CONTROL OF THAT MECHANISM. THEIR EXPANDED INSIGHTS HAVE ALREADY LED TO: 1.) A POWERFUL VACCINE CANDIDATE TARGETED FOR LONG TERM PREVENTION OF MALARIA INFECTION; 2.) A THERAPEUTIC ANTIBODY CANDIDATE FOR SHORT TERM MALARIA PREVENTION; AND 3.) A THERAPEUTIC SMALL MOLECULE DRUG CANDIDATE TARGETED TO TREAT SEVERE MALARIA, WITH POTENTIAL TO LAUNCH A WHOLE NEW CLASS OF MALARIA MEDICINES.

OCEAN BIOMEDICAL, INC. (NASDAQ: OCEA) ANNOUNCES PATENT ISSUED FOR PFGARP MALARIA ANTIBODIES CENTRAL TO COMPANY'S MALARIA TREATMENT AND PREVENTION PLATFORMS

PROVIDENCE, RHODE ISLAND, AUG. 23, 2024 (GLOBE NEWSWIRE) -- OCEAN BIOMEDICAL, INC. (NASDAQ: OCEA), TODAY ANNOUNCED THAT ON AUGUST 19, 2024, IT RECEIVED A NOTICE FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) STATING THAT BECAUSE THE COMPANY HAS NOT YET FILED ITS QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2024 (THE FORM 10-Q), THE COMPANY IS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5250(C)(1), WHICH REQUIRES LISTED COMPANIES TO TIMELY FILE ALL REQUIRED PERIODIC REPORTS WITH THE SECURITIES AND EXCHANGE COMMISSION (THE SEC).

PROVIDENCE, RI, JUNE 05, 2024 (GLOBE NEWSWIRE) -- OCEAN BIOMEDICAL, INC. (NASDAQ: OCEA ), A BIOPHARMA COMPANY WORKING TO ACCELERATE THE DEVELOPMENT OF COMPELLING DISCOVERIES FROM TOP RESEARCH SCIENTISTS, TODAY CONGRATULATES ITSJV PARTNER VIRION THERAPEUTICS, LLC, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPINGNOVEL T CELL-BASED IMMUNOTHERAPIES, ON ITS LATE BREAKER PRESENTATION HIGHLIGHTING THE FIRST-EVER HUMAN IMMUNOGENICITY DATA FROM ITS NOVEL CHECKPOINT MODIFIER IMMUNOTHERAPY FOR HBV FUNCTIONAL CURE (VRON-0200), AT THE EASL 2024 CONGRESS (THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER), TAKING PLACE IN MILAN, ITALY FROM JUNE 5 - 8.

OCEAN BIOMEDICAL (NASDAQ: OCEA) CONGRATULATES JOINT VENTURE PARTNER, VIRION THERAPEUTICS, ON POSITIVE IMMUNOGENICITY RESULTS FROM THEIR LEAD CHECKPOINT MODIFIER-CONTAINING IMMUNOTHERAPY, VRON-0200, FOR HBV FUNCTIONAL CURE, AT EASL 2024

PROVIDENCE, RHODE ISLAND, MAY 30, 2024 (GLOBE NEWSWIRE) -- OCEAN BIOMEDICAL, INC.(NASDAQ:OCEA), TODAY ANNOUNCED THAT ON MAY 22, 2024, IT RECEIVED A NOTICE FROMTHE NASDAQ STOCK MARKET LLC(NASDAQ) STATING THAT BECAUSE THE COMPANY HAS NOT YET FILED ITS QUARTERLY REPORT ON FORM10-QFOR THE PERIOD ENDED MARCH 31, 2024(THE FORM10-Q),THE COMPANY IS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5250(C)(1), WHICH REQUIRES LISTED COMPANIES TO TIMELY FILE ALL REQUIRED PERIODIC REPORTS WITH THESECURITIES AND EXCHANGE COMMISSION(THE SEC).

Ocean Biomedical, Inc.

OCEA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Ocean Biomedical, Inc.

OCEA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

OCEA